Paul Vincent Grootendorst
Names
| first: |
Paul |
| middle: |
Vincent |
| last: |
Grootendorst |
Identifer
Contact
Affiliations
-
University of Toronto
/ Munk School of Global Affairs and Public Policy (weight: 10%)
-
University of Toronto, Faculty of Pharmacy (weight: 80%)
- http://www.pharmacy.utoronto.ca/
- location: Canada, Toronto
-
McMaster University
/ Department of Economics (weight: 10%)
Research profile
author of:
- The Effects of Drug Subsidies on Out-of-Poket Prescription Drug Expenditures by seniors: regional Evidence from Canada (RePEc:auu:dpaper:422)
by Thomas F. Crossley & Paul Grootendorst & Sule Kokkmaz & Michael R. Veall - Intellectual Property Protection And Drug Plan Coverage: Evidence From Ontario (RePEc:cch:wpaper:150005)
by Paul Grootendorst & Minsup Shim & Adam Falconi & Tyler Robinson & Ethar Ismail & Joel Lexchin - An Empirical Examination of the Patented Medicine Prices Review Board Price Control Amendments on Drug Launches in Canada (RePEc:cch:wpaper:200003)
by Oliver Spicer & Paul Grootendorst - Distributional effects of `general population' prescription drug programs in Canada (RePEc:cje:issued:v:38:y:2005:i:1:p:128-148)
by Sule Alan & Thomas Crossley & Paul Grootendorst & Michael Veall - New Approaches to Rewarding Pharmaceutical Innovation (RePEc:cla:levrem:661465000000000169)
by Paul Grootendorst & Aidan Hollis & David K Levine & Thomas Pogge & Aled M Edwards - An Empirical Analysis of Milk Addiction (RePEc:clg:wpaper:2001-17)
by Christopher Auld & Paul Grootendorst - National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations? (RePEc:cpp:issued:v:31:y:2005:i:4:p:341-358)
by Paul V. Grootendorst & Michael R. Veall - The cost of drug development: A systematic review (RePEc:eee:hepoli:v:100:y:2011:i:1:p:4-17)
by Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon - The effect of patented drug price on the share of new medicines across OECD countries (RePEc:eee:hepoli:v:126:y:2022:i:8:p:795-801)
by Spicer, Oliver & Grootendorst, Paul - On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective (RePEc:eee:hepoli:v:55:y:2001:i:2:p:97-109)
by Schneeweiss, Sebastian & Maclure, Malcolm & Walker, Alexander M. & Grootendorst, Paul & Soumerai, Stephen B. - The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada (RePEc:eee:hepoli:v:84:y:2007:i:1:p:1-13)
by Marshall, Deborah A. & Willison, Donald J. & Grootendorst, Paul & LeLorier, Jacques & Maclure, Malcolm & Kulin, Nathalie A. & Sheehy, Odile E. & Warren, Leanne & Sykora, Kathy & Rahme, Elham - The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada (RePEc:eee:jhecon:v:21:y:2002:i:5:p:805-826)
by Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R. - An empirical analysis of milk addiction (RePEc:eee:jhecon:v:23:y:2004:i:6:p:1117-1133)
by Auld, M. Christopher & Grootendorst, Paul - Prescription Drug Insurance and Reimbursement (RePEc:elg:eechap:14021_11)
by Paul Grootendorst - Prescription Drug Insurance and Reimbursement (RePEc:elg:eechap:3572_11)
by Paul Grootendorst - Results of an Investigation into the Integrity of the Ontario Health Survey (RePEc:hpa:wpaper:199311)
by Paul Grootendorst - Does It Matter Whom and How You Ask? Inter and Intra-rater Agreement in the Ontario Health Survey (RePEc:hpa:wpaper:199412)
by P Grootendorst & D Feeny & W Furlong - On Becoming 65 in Ontario: Effects of Provincial Drug Plan Eligibility on Utilization of Prescription Medicines (RePEc:hpa:wpaper:199501)
by P Grootendorst & B O'Brien & G Anderson - Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare (RePEc:hpa:wpaper:199608)
by Paul Grootendorst & Laurie Goldsmith & Jeremiah Hurley & Bernie O'Brien & Lisa Dolovich - Variance in Pharmacare Coverage Across Canada (RePEc:hpa:wpaper:199808)
by Donald Willison & Paul Grootendorst & Jeremiah Hurley - Health Utilities Index Mark 3: Evidence of Construct Validity for Stroke and Arthritis in a Population Health Survey (RePEc:hpa:wpaper:199906)
by P Grootendorst & D Feeny & W Furlong - Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment (RePEc:hpa:wpaper:199910)
by P Grootendorst - International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada (RePEc:hpa:wpaper:200108)
by Donald Willison & Mary Wiktorowicz & Paul Grootendorst & Bernie O'Brien & Mitchell Levine & Raisa Deber & Jeremiah Hurley - Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs (RePEc:iza:izadps:dp695)
by Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R. - Evidence of Construct Validity for Stoke and Arthritis in a Population Health Survey (RePEc:mcm:deptwp:1999-09)
by Paul Grootendorst & David Feeney & W. Furlong - The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada (RePEc:mcm:qseprr:350)
by Thomas F. Crossley & Paul Grootendorst & Sule Korkmaz & Michael R. Veall - The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume I: Summary (RePEc:mcm:qseprr:369)
by Paul V. Grootendorst & Lisa R. Dolovich & Anne M. Holbrook & Adrian R. Levy & Bernie J. O'Brien - The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report (RePEc:mcm:qseprr:370)
by Paul V. Grootendorst & Lisa R. Dolovich & Anne M. Holbrook & Adrian R. Levy & Bernie J. O'Brien - Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population (RePEc:mcm:qseprr:372)
by Paul Grootendorst & Mitchell Levine - Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs (RePEc:mcm:qseprr:379)
by Sule Alan & Thomas F. Crossley & Paul Grootendorst & Michael R. Veall - National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations? (RePEc:mcm:qseprr:385)
by Thomas F. Crossley & Paul V. Grootendorst & Michael R. Veall - National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations? (RePEc:mcm:sedapp:105)
by Thomas F. Crossley & Paul V. Grootendorst & Michael R. Veall - The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs (RePEc:mcm:sedapp:115)
by Paul V. Grootendorst & John K. Marshall & Anne M. Holbrook & Lisa R. Dolovich & Bernie J. O'Brien & Adrian R. Levy - The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada (RePEc:mcm:sedapp:19)
by Thomas F. Crossley & Paul Grootendorst & Sule Korkmaz & Michael R. Veall - Effects of 'Authorized-Generics' on Canadian Drug Prices (RePEc:mcm:sedapp:201)
by Paul Grootendorst - A review of instrumental variables estimation in the applied health sciences (RePEc:mcm:sedapp:215)
by Paul Grootendorst - The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature (RePEc:mcm:sedapp:221)
by Paul Grootendorst & Emmanuelle Piérard & Minsup Shim - How should we support pharmaceutical innovation? (RePEc:mcm:sedapp:246)
by Paul Grootendorst - Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation? (RePEc:mcm:sedapp:250)
by Paul Grootendorst - The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume I: Summary (RePEc:mcm:sedapp:70)
by Paul V. Grootendorst & Lisa R. Dolovich & Anne M. Holbrook & Adrian R. Levy & Bernie J. O'Brien - The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia--Volume II: Technical Report (RePEc:mcm:sedapp:71)
by Paul V. Grootendorst & Lisa R. Dolovich & Anne M. Holbrook & Adrian R. Levy & Bernie J. O'Brien - Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population (RePEc:mcm:sedapp:73)
by Paul V. Grootendorst & Mitchell Levine - Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs (RePEc:mcm:sedapp:88)
by Sule Alan & Thomas F. Crossley & Paul Grootendorst & Michael R. Veall - Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey (RePEc:mos:moswps:2011-31)
by Guy E.J. Faulkner & Paul Grootendorst & Van Hai Nguyen & Tatiana Andreyeva & Kelly Arbour-Nicitopoulos & Chris Auld & Sean B. Cash & John Cawley & Peter Donnelly & Adam Drewnowski & Laurette Dubé & R - Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology (RePEc:spr:pharmo:v:1:y:2017:i:3:d:10.1007_s41669-017-0022-7)
by Kavisha Jayasundara & Murray Krahn & Muhammad Mamdani & Jeffrey S. Hoch & Paul Grootendorst - Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada (RePEc:taf:applec:v:46:y:2014:i:10:p:1081-1092)
by Emmanuelle Pi鲡rd & Paul Grootendorst - Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics (RePEc:taf:ijecbs:v:22:y:2015:i:2:p:201-217)
by Ali Shajarizadeh & Paul Grootendorst & Aidan Hollis - Distributional effects of ‘general population’ prescription drug programs in Canada (RePEc:wly:canjec:v:38:y:2005:i:1:p:128-148)
by Sule Alan & Thomas F. Crossley & Paul Grootendorst & Michael R. Veall - Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada (RePEc:wly:hlthec:v:14:y:2005:i:9:p:909-923)
by Paul Contoyannis & Jeremiah Hurley & Paul Grootendorst & Sung‐Hee Jeon & Robyn Tamblyn - A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British Columbia (RePEc:wly:hlthec:v:15:y:2006:i:7:p:735-742)
by Paul Grootendorst & David Stewart - Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator (RePEc:wly:hlthec:v:6:y:1997:i:4:p:365-382)
by Paul V. Grootendorst - Does rising income inequality affect mortality rates in advanced economies? (RePEc:zbw:ifwedp:201712)
by Rebeira, Mayvis & Grootendorst, Paul V. & Coyte, Peter C. & Aguirregabiria, Victor - Does rising income inequality affect mortality rates in advanced economies? (RePEc:zbw:ifweej:201716)
by Rebeira, Mayvis & Grootendorst, Paul & Coyte, Peter C. & Aguirregabiria, Victor